

PRIVATE EQUITY SOLUTIONS

PE Market Impact & Portfolio Update June 4, 2020

Visit us: www.go.dws.com/pe

Marketing material. For professional investors only.

For Professional Clients (MiFID Directive 2014/65/EU Annex II) only.

Not for retail distribution.

DWS has prepared the material above based on data provided by third parties. DWS does not guarantee The accuracy and completeness of this information. Past performance is not indicative of future returns. There is no assurance that investment objectives will be achieved. This presentation is intended only for the exclusive benefit and use of our clients and prospects. This presentation was prepared, in order to illustrate, on a preliminary basis, a specific investment strategy and does not carry any right of publication or disclosure. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of DWS.

CONTENTS



- 01 PE Market Covid Impact
- Our Perspective and Market Positioning
- 03 Executed Transactions
- 04 Current Opportunity Set
- 05 Team Biographies
- 06 Disclosures



WHAT'S REALLY HAPPENING IN PE FUNDS?



PE has reacted quickly but every fund is facing a different impact

01

Phase One: Q1

What's happening in my portfolio companies?

- 24/7 info gathering
- Focus on liquidity (bank lines, fund lines, LP capital calls)
- Lender (re)negotiations
- Triage portfolio

02

Phase Two: Q2

'Enforced' stability & defensive add-ons

- Cash injections
- Government support (where possible) and unwinding deals (where possible)
- Watch and wait
- Bid/ask spread

03

Phase Three: H2

Opportunistic add-ons and M&A

- Focus on winners
- Add-ons and selective M&A
- Stabilize other assets
- More intense discussions with lenders

Investors won't really know what's happening until Q2 valuations are published (usually September)

WINNERS AND LOSERS



Underlying sector exposure will be a key determinant in private equity portfolio performance



Sector expertise and cycle tested management teams have become more critical than ever


^{1.} Credit Suisse PFG (May 2020) based on reported Q1 valuations across strategies in PE. Source: DWS Private Equity as at May 2020. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize.

EMERGING THEME IN THE COVID ERA



DWS expects bid/ask pricing gaps to remain throughout 2020 and into next year

To bridge the gap on pricing, buyers are increasingly negotiating downside protection and greater alignment with sellers through various mechanisms such as the inclusion of structured equity, larger management rollovers, and performance based earn-outs




COVID IMPACT: EXIT ENVIRONMENT




Likely to extend hold periods and demand more net capital from LPs

KEY POINTS

- Following the GFC, buyout exit volume decline in subsequent two years leading to longer hold periods for existing portfolio companies
- Impact of this crisis still early, but previously unimaginable halt to trading has made underwriting new investments, corporate acquisitions, or IPOs extremely difficult
- Focus on stabilizing companies and preventing potential bankruptcies will also require an increase in Private Equity capital calls to LPs, putting further pressure on returns.
- Current environment provides plenty of opportunities for structured financing or other sources of alternative capital



ANNUAL BUYOUT CONTRIBUTIONS VS DISTRIBUTIONS (\$BN)




Sources: DWS CIO View (May 2020), Evercore Market Update Report (April 2020) & Preqin (2020).

Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize.

VALUE PROPOSITION TO SPONSORS



PES can be an attractive alternative for GPs to invest more in existing assets



| Capital Source | PES Alternative |
|------------------|--|
| Debt Market | ✓ Greater flexibility over use of funds✓ Equity can expand borrowing base |
| Competitor GPs | ✓ Trusted, unthreatening counterparty ✓ Faster negotiations with greater transparency of information ✓ More aligned governance |
| LP Co-Invest | ✓ True third-party valuation and structure ✓ LPs may co-invest alongside PES |
| GP-Led Secondary | ✓ Much lower complexity ✓ No change to original fund structure and terms ✓ Faster execution / certain execution |

Source: DWS Private Equity as at May 2020. The information herein reflects our current views only, is subject to change, are not intended to be promissory or relied upon by the reader. There can be no certainty that events will turn out as we have opined herein. For illustrative purposes only.

PE CONTROL SPONSOR CAPITAL SOLUTIONS



Covid has materially impacted traditional capital solutions

Debt Market

Senior Debt retrenching Subordinated Debt at better terms (for lender) and larger deals





Private Equity Solutions

Partial exits more realistic/attractive Sponsors see attractive add-ons Re-equitisation of balance sheets



Limited Partners

Focused on existing commitments

Adjusting to Covid-19 constraints on deal policies and protocols

Denominator effect





GP-Led Secondary

Valuation challenges

Traditional buyers in a "wait and see" mode as they wait for the market to clear and reset



Flexibility



Less attractive / available



More attractive / available






Net Neutral

ACCESS TO ATTRACTIVE PRIVATE MARKET ASSETS



Seeking to mitigate risk by investing in seasoned, performing assets





Capital for Growth

- Add-ons
- · Organic growth initiatives
- · Vertical integration
- Product investment



Minority Capital

- · Partial exit and DPI to LPs
- · Buyout other shareholders
- · Consolidate sponsor control



Continuation Capital

- Enable sponsor to pursue greater returns from their key assets
- Taking advantage of identified catalysts for further growth

Bespoke structures seeking to mitigate risk and ensure alignment: Liquidation Preferences, Exit Veto, Put Options, Sponsor & Management Investments, etc.

Source: DWS Private Equity as at January 2020. No assurance can be given that any forecast or target will be achieved; for illustrative purposes only.

The information herein reflects our current views only, is subject to change, and is not intended to be promissory or relied upon by the reader. There can be no certainty that events will turn out as we have opined herein. There is no assurance that investment objectives can be achieved. Please refer to Risk Factors in the offering document for important information.




OUR APPROACH TO RISK MITIGATION



Various levers seek to enhance the risk / return profile of our transactions

ENTRY POINT & HOLD PERIOD¹



Source: DWS Private Equity and Control Sponsors.

- By transaction or representative company within a transaction as a proxy. Exit timing is indicative only
 and should not be relied upon as a firm exit date for any investment.
- 2. Payout analysis based on changes in enterprise value. Participating Preferred Equity providing downside protection via a 1.0x liquidation preference to common equity.


The information herein reflects our current views only, is subject to change, and is not intended to be promissory or relied upon by the reader. There can be no certainty that events will turn out as we have opined herein. There is no assurance that investment objectives can be achieved and there is no guarantee against loss. Please refer to Risk Factors in the offering document for important information.

OUR PHILOSOPHY

Continuing to back performing assets

- ✓ Entering later into the hold period at an attractive entry point
- More aligned due diligence and information flow
- Where possible, seeking to create additional protection via a bespoke structure

TRANSACTION STRUCTURE - NUTRACEUTICAL²



WHO WE WORK WITH























PES PORTFOLIO - COVID IMPACT TO DATE



Robust portfolio with structures seeking to mitigate risk

- ✓ Portfolio proving robust with some companies seeing increased demand
- ✓ One asset representing 8% of cost appears vulnerable; PES holds the senior-most security in that asset
- ✓ Downside protections through structures (liquidity preference, senior securities, put option) provide additional comfort

| Investment | Invested (\$m)¹ | NAV (\$m)¹ | Gross Multiple¹ | Liquidity | Current Covid Impact |
|---|--------------------|---------------|--------------------|-----------|--|
| Cegal Group | 20.3 | 21.1 | 1.04x | Strong | Increased demand for some services. Operating at budget to date. |
| Grant & Stone | 11.6 | 11.9 | 1.03x | Strong | Some site closures and reduced demand. Operating at cashflow break-even |
| Upstream Rehabilitation ² | 24.0 | 29.9 | 1.24x | Strong | Some site closures and reduced demand. Operating at cashflow break-even |
| Nutraceutical | 20.1 | 20.0 | 1.00x | Strong | Increased demand for some products. At or above budget to date |
| Pacific Growth Investors | 15.6 | 22.6 | 1.46x | Weak | Sandel (\$8m cost, \$12m NAV) requires further near- term funding. PES holds senior, first-out loan notes |
| Cambridge Innovation Capital | 10.4 | 13.8 | 1.33x | Neutral | Delaying some portfolio company progress but no material impact overall. |
| Total | 102.0 | 119.3 | 1.17x | | |

Source: DWS Private Equity and Sponsors, as at May 2020.

^{1.} NAV and Gross Multiple as at December 31, 2019 (audited). 2. Includes \$5m commitment to Revelstoke Capital Partners II



NUTRACEUTICAL



Structured minority investment

Transaction Summary



| Sector | Consumer Staples |
|------------------|--|
| Asset Type | Buyout |
| Country | United States |
| GP | Snapdragon Capital Partners / HGGC |
| Sourcing | Proprietary |
| Transaction Type | Minority Capital |
| Description | Manufacturer and distributor of vitamins, minerals & supplements |

Deal Statistics

| Transaction Date | July 2019 |
|-----------------------|---------------------|
| Commitment | \$21.6m |
| Target Returns to PES | 2.0x MOIC / 17% IRR |
| TV/TC as at Dec 2019 | 1.00x |

DWS has prepared, where applicable, the material in this section based on data provided third parties. DWS does not guarantee the accuracy and completeness of this information. There is no assurance that investment objectives will be achieved. For illustrative purposes only. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the markets covered may differ materially from those described. * Target return expectations for investments have been formed through historical operating and valuation performance coupled with forward looking expectations from the financial sponsor, company management, and PES's view of underlying company performance over our hold period. Please refer to Risk Factors in the Investment Memorandum for important information.


INVESTMENT THESIS

- Capitalizing on strong secular growth in the nutritional supplements industry, which
 has historically exhibited steady growth of approximately 6% over the past 20 years
 with modest economic sensitivity.
- Investing in a market-leading player that has a demonstrated long-term record of performance and has experienced an acceleration in earnings since being acquired by HGGC in 2017 through operational improvements and targeted acquisitions.
- Control sponsor to continue to seek to unlock value with targeted M&A complemented by a renewed emphasis on direct to consumer channels supported by new key partnerships.

PES FIT & TRANSACTION STRUCTURE

- The PES investment provides access to a seasoned, strongly performing private market company with strong momentum and clearly identified opportunities to continue to grow earnings.
- Control sponsor (HGGC) continues to execute on plan to seek to unlock value to capture additional return from a performing asset.
- The transaction facilitates the engagement of operating partners and minority control sponsors Snapdragon Capital Partners and The Maze Group who are well positioned to further unlock value in historically under-emphasized sales channel.
- Participating Preferred Equity providing downside protection via a 1.0x liquidation preference to common equity. Veto right on a sale producing less than 2.0x gross MOIC for 5 years

PAYOUT ANALYSIS BASED ON CHANGES IN ENTERPRISE VALUE



NUTRACEUTICAL



Structured minority investment

COVID IMPACT

Positives:

- Demand for products has been very strong. Beat revenue budget in March by 20% (40% yoy growth). April so far is performing ahead of budget.
- Sales have been strong in online (Amazon and other resellers) and surprisingly resilient in other channels (i.e. HFS, major retailers).
- Although some smaller health stores are affected by this crisis, Nutraceutical has successfully pivoted to larger stores better able to weather the crisis.
- Strong liquidity position. Drew down from revolver early on to provide extra buffer.

Challenges:

- Production of products reliant on contract manufacturing (i.e. gummies) has been impacted.
- Potential risk of future disruption as manufacturing concentrated in one facility.
- Some disruption to raw materials supply chain.

VALUE CREATION DRIVERS

- Continuing operational improvements implemented following HGGC ownership, i.e. manufacturing consolidation, implementing ERP systems and optimizing capacity utilization
- Build-out of sales data and supporting technology to better empower sales staff
- Executing on DTC strategy
- Growing and optimizing presence in online marketplaces

GRANT & STONE



Structured investment in UK building materials merchant

Transaction Summary



| Sector | Industrials |
|------------------|--|
| Asset Type | Buyout |
| Country | United Kingdom |
| GP | Cairngorm Capital |
| Sourcing | Proprietary |
| Transaction Type | Minority capital |
| Description | Building materials merchant in SE England |

Deal Statistics

| Transaction Date | November 2019 |
|-----------------------|--|
| PES I Commitment | £9.6m |
| Target Returns to PES | 3.6x MOIC / 45% IRR – Equity; 15% IRR - Put |
| TV/TC as at Dec 2019 | 1.03x |

Source: Materials received from Cairngorm Capital; DWS Private Equity diligence (November 2019).


DWS has prepared, where applicable, the material in this section based on data provided third parties. DWS does not guarantee the accuracy and completeness of this information. There is no assurance that investment objectives will be achieved. For illustrative purposes only. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the markets covered may differ materially from those described. *Target return expectations for investments have been formed through historical operating and valuation performance coupled with forward looking expectations from the financial sponsor, company management, and PES's view of underlying company performance over our hold period. Please refer to Risk Factors in the Investment Memorandum for important information.

INVESTMENT THESIS

- Established performing business within a prime region of the U.K. with significant opportunities for consolidation and synergy extraction.
- Partnering with a sponsor who has significant experience in the sector and has already successfully executed the same strategy with an existing portfolio company in a similar geography.
- Opportunity for PES to generate further value through add-on investments at the original equity entry valuation.

PES FIT & TRANSACTION STRUCTURE

- Reduced information asymmetry risk from transaction structure.
- Right of First Refusal on pre-identified add-on investments at the same equity entry valuation as the original day-one investment.
- DWS and Cairngorm teams have a history with the asset and the sector.
- Put option earning 15% IRR with full upside participation through the ability to retain the investment or exercise the put back to the sponsor¹.



^{1.} The put is exercisable where the company takes on leverage and repays the Cairngorm equity bridge (equity received from Cairngorm Fund III).

Source: DWS Private Equity as at May 2020. Forecasts are based on assumptions, estimates, views and hypothetical models or analyses, which might prove inaccurate or incorrect.

GRANT & STONE



Structured investment in UK building materials merchant

COVID IMPACT

Positives:

- After initially closing all 29 sites, 28 sites have now re-opened and are running at or around cash breakeven.
- Gross margins have increased due to strong demand.
- Strong liquidity position going into the end of March from excellent prior cashflow conversion and currently no bank debt.
- Opportunity to acquire add-on assets at attractive values.
- Sponsor maintains conviction in longer-term investment proposition
- PES has strong downside protection through its put option right (at cost +15% IRR) exercisable in certain circumstances¹.

Challenges:

- Site revenues are down 50% y-o-y in Covid period compared to 2019.
- 2020 performance is unlikely to match initial expectations.
- There is a risk that government enforces stricter controls and sites are required to close.

VALUE CREATION DRIVERS

- Improve gross margins and achieve operational efficiencies
- Drive organic revenue growth through new branch openings and additional sales initiatives
- Execute bolt-on acquisitions at attractive pricing and grow regional footprint
- Position business as natural target for larger PE-owned or national trade players

^{1.} The put is exercisable where the company takes on leverage and repays the Cairngorm equity bridge (equity received from Cairngorm Fund III). Source: DWS Private Equity as at May 2020 and Grant & Stone Financial Reports.

ELECTRICAL SOURCE HOLDINGS ("ESH")



Growth investment in a critical aftermarket electrical distributor

Transaction Summary



| Sector | Industrials |
|------------------|---|
| Asset Type | Buyout |
| Country | United States |
| GP | Emerald Lake / Greenbriar Equity |
| Sourcing | Limited process |
| Transaction Type | Growth capital |
| Description | Aftermarket electrical parts distribution |

Deal Statistics

| Transaction Date | May 2020 |
|-----------------------|---------------------|
| PES I Commitment | \$16.0m |
| Target Returns to PES | 2.6x MOIC / 24% IRR |

DWS has prepared, where applicable, the material in this section based on data provided third parties. DWS does not guarantee the accuracy and completeness of this information. There is no assurance that investment objectives will be achieved. For illustrative purposes only. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the markets covered may differ materially from those described. *Target return expectations for investments have been formed through historical operating and valuation performance coupled with forward looking expectations from the financial sponsor, company management, and PES's view of underlying company performance over our hold period. Please refer to Risk Factors in the Investment Memorandum for important information.

COMPANY DESCRIPTION

- ESH is the largest value-added North American distributor of after-market electrical components, such as circuit breakers, for industrial and commercial businesses
- The Company offers mission critical new-replacement and reconditioned components for emergency situations, where an electrical failure has caused unexpected facility downtime and the potential for missed revenue opportunities
- ESH's comprehensive inventory consists of primarily older model parts which are difficult to source for smaller players and hold material scarcity value.
- ESH's core value proposition is the ability to pull from a large inventory and the flexibility to provide same or next day delivery from its various facilities

INVESTMENT THESIS

- Facilitate the combination of ESH with another established, diversified platform in critical replacement electrical components, with consistently high margins, valuable inventory, and demonstrated resilience over business cycles.
- Backing a sponsor and management team with several decades of experience in electrical distribution, including at major wholesale partners of ESH. Emerald Lake's operating partner is the Chairman of ESH and has a 15 year history working with ESH's CEO as his direct manager in prior roles.
- Attractive opportunity to further pursue accretive add-on acquisitions given a highly fragmented industry and strong pipeline of warm targets.

PES FIT & TRANSACTION STRUCTURE

- Electrical Source aligns with the core PES mandate to invest in high-quality, strongly performing private market companies with clearly identified paths to further growth.
- PES entry point of c.9.7x represents a nearly 3x reduced implied platform creation multiple from the GP's entry, despite solid performance and four completed add-on acquisitions
- Reduced information asymmetry risk due to the sponsor's long-term relationship with the Company and the CEO

ELECTRICAL SOURCE HOLDINGS ("ESH")



Growth investment in a critical aftermarket electrical distributor

COVID IMPACT

Positives:

- Revenue impact mitigated by significant number of essential businesses (ex. utilities, hospitals, data centers) in the customer base.
- Management expects flat year-over-year EBITDA performance for the June YTD period, driven by recent price initiatives, material cost reductions and synergy realizations.
- Surge of demand is anticipated as systems restart, given circuit breakers and other older electrical components are not suited to being shut off for extended periods.
- Company has substantial cushion from existing liquidity (\$14mm cash on hand and \$10mm+ revolver capacity), covenant headroom (max net leverage of 9.75x), and strong cash generation due to high margins and limited capital expenditures.

Challenges:

- Platform revenues have shown some weakness YTD through Mid-May (2.0% revenue decline); however, as the economy has begun to open up, the Company has seen a positive sales trajectory over multiple weeks.
- Gross profit has fallen largely consistent with revenue, as margins have remained stable.
- Extended social distancing guidelines could drive further difficulty as certain customer facilities remain shutdown.

VALUE CREATION DRIVERS

- Grow existing customer accounts through expansion into underserved branches with preferred supplier relationships
- Win new client accounts through management team's relationships and an enhanced salesforce
- Drive further ancillary product cross-selling
- Implement coordinated pricing strategy across footprint
- Execute additional add-on acquisitions at both accretive and de-levering multiples

CEGAL GROUP



Cloud solutions and software provider

Transaction Summary



| Sector | Information Technology |
|------------------|---|
| Asset Type | Buyout |
| Country | Norway |
| GP | Norvestor Equity AS |
| Sourcing | Proprietary |
| Transaction Type | Continuation Capital |
| Description | Cloud solutions and software provider to the oil & gas industry |

Deal Statistics

| Transaction Date | December 2019 |
|-----------------------|---------------------|
| Commitment | \$22.2m |
| Target Returns to PES | 2.8x MOIC / 40% IRR |
| TV/TC as at Dec 2019 | 1.04x |

DWS has prepared, where applicable, the material in this section based on data provided third parties. DWS does not guarantee the accuracy and completeness of this information. There is no assurance that investment objectives will be achieved. For illustrative purposes only. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the markets covered may differ materially from those described. * Target return expectations for investments have been formed through historical operating and valuation performance coupled with forward looking expectations from the financial sponsor, company management, and PES's view of underlying company performance over our hold period. Please refer to Risk Factors in the Investment Memorandum for important information.

INVESTMENT THESIS

- Cegal has shown its caliber as a high-growth high-margin business during the period of the sponsor's ownership since 2011.
- Diligence identified growing momentum in sales driven by moving clients onto larger SaaS (Software as a Service) model contracts with recurring revenues and lower capex requirements, indicating potential for an inflection point in the sponsor value creation thesis.
- Favorable market fundamentals as the oil and gas industry increasingly digitizes and adopts outsourced cloud services.
- Experienced management team and a control sponsor with a proven track record.

PES FIT & TRANSACTION ALIGNMENT

- Cegal reflects the core thesis of PES of identifying high-quality, strongly performing private market companies with clearly identified paths to further growth.
- Strong performance momentum and reduced information asymmetry as the PES investment facilitates the retention of the asset by the sponsor who first acquired the asset in 2011.
- DWS, Norvestor and Cegal management have strong alignment due to new SPV including a commitment from the Norvestor team and a significant management roll.

CEGAL GROUP



Cloud solutions and software provider

COVID IMPACT

Positives:

- Company performing on plan to date, supported by long term contracts.
- Cloud services product helps customers work from home.
- Pipeline remains strong, Covid has generated new leads.
- Debt does not contain maintenance covenants.

Challenges:

- Persistent low oil prices may result in slower growth if customers delay digitization and cloud initiatives
- Distancing measures increase complexity of sales activities and implementation of current projects.
- Customers may seek to negotiate price reductions.
- Oil services customers most sensitive to downturn.

VALUE CREATION DRIVERS

- Expansion of services with existing & new clients
- Increased focus on cloud hosting & services
- Conversion of customers to SaaS model
- Gradual shift from private cloud to public cloud contracts will improve cash flow
- Upside opportunities through M&A / cross-selling

UPSTREAM REHABILITATION



Continuation vehicle for leading multi-state physical therapy operator

Transaction Summary



| Sector | Health Care |
|------------------|--|
| Asset Type | Buyout |
| Country | United States |
| GP | Revelstoke Capital Partners |
| Sourcing | Advised |
| Transaction Type | Continuation Capital |
| Description | Multi-state operator of physical therapy clinics |

Deal Statistics

| Transaction Date | November 2019 |
|-------------------------|---------------------|
| Commitment ¹ | \$30.0m |
| Target Returns to PES | 2.2x MOIC / 18% IRR |
| TV/TC as at Dec 20191 | 1.24x |

DWS has prepared, where applicable, the material in this section based on data provided third parties. DWS does not guarantee the accuracy and completeness of this information. There is no assurance that investment objectives will be achieved. For illustrative purposes only. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the markets covered may differ materially from those described. * Target return expectations for investments have been formed through historical operating and valuation performance coupled with forward looking expectations from the financial sponsor, company management, and PES's view of underlying company performance over our hold period. Please refer to Risk Factors in the Investment Memorandum for important information.

INVESTMENT THESIS

- Favorable market fundamentals as the U.S. physical therapy industry is benefitting from several secular tailwinds (e.g. aging population, increasing adoption of physical therapy, and growth in employment benefits).
- Established platform with multiple avenues for growth by continuing to execute on a thematic approach to consolidation in a highly fragmented physical therapy market.
- Unique minority ownership business model has driven strong employee retention and best in class KPIs.

PES FIT & TRANSACTION STRUCTURE

- Upstream reflects the PES core thesis of identifying high quality private market companies backed by strong sponsors at inflection points with clear pathways to additional value creation.
- The DWS team has a history with the asset and the physical therapy sector, with two members of the diligence team executing the original transaction alongside the sponsor in 2015 while at different firms, and transacting on similar assets in the space.
- The PES transaction creates a capital structure which better facilitates clinic roll-outs and tuck-in acquisitions, with meaningful capital reserves to pursue transformative M&A as regional and nation-wide opportunities arise over the coming years.
- DWS invested in the transaction late in the syndicate build, following stronger than expected performance, leading to an effective entry multiple of 12.9x LTM PF Adj. EBITDA versus an entry multiple of 14.5x when the deal was originally signed in 1H 2019.

Source: DWS Private Equity as at May 2020. Forecasts are based on assumptions, estimates, views and hypothetical models or analyses, which might prove inaccurate or incorrect.

^{1.} Includes \$5 million commitment to Revelstoke Capital Partners Fund II.

UPSTREAM REHABILITATION



Continuation vehicle for leading multi-state physical therapy operator

COVID IMPACT

Positives:

- Upstream's YTD February performance was very strong with YTD February Net Revenue up 11% yoy and YTD February Visits up 14% yoy.
- Significant diversification across 26 states and over 770 clinics (mix of urban, suburban and rural locations).
- Strong liquidity position with ~\$45 million of cash (~\$75 million when including 30-60+ days receivables) on the balance sheet and has no financial covenants.
- Physical therapy is an essential service as defined by the American Disabilities Act and as such Upstream will keep their network largely open.

Challenges:

- The Company had begun to see an impact on volume / visits in March and are preparing for further slowdowns over April and potentially into May.
- Although Revelstoke expects a temporary volume decline, they do expect to regain these volumes once the current situation passes.
- The Company has furloughed ~2,600 employees and terminated ~200 staff converted ~350 salaried employees to hourly, reduced salaries of top ~35 employees, temporarily closed 143 clinics.

VALUE CREATION DRIVERS

- Continued positive same-store sales growth, particularly in acquired clinics
- Roll-out of big box and small box de novos
- Tuck-in and transformative acquisition opportunities

PACIFIC GROWTH INVESTORS



Structured equity investments into 3 companies

Transaction Summary

| Sector | Industrials | | | |
|------------------|--|--|--|--|
| Asset Type | Growth | | | |
| Country | United States | | | |
| GP | Pacific Growth Investors | | | |
| Sourcing | Proprietary | | | |
| Transaction Type | Capital for Growth | | | |
| Description | Growth capital investment into 3 PGI assets selected by the PES team | | | |

Deal Statistics

| Transaction Date | December 2018 |
|-----------------------|---------------------|
| PES I Commitment | \$15.6m |
| Target Returns to PES | 2.4x MOIC / 35% IRR |
| TV/TC as at Dec 2019 | 1.45x |

DWS has prepared, where applicable, the material in this section based on data provided third parties. DWS does not guarantee the accuracy and completeness of this information. There is no assurance that investment objectives will be achieved. For illustrative purposes only. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the markets covered may differ materially from those described. * Target return expectations for investments have been formed through historical operating and valuation performance coupled with forward looking expectations from the financial sponsor, company management, and PES's view of underlying company performance over our hold period. Please refer to Risk Factors in the Investment Memorandum for important information.


INVESTMENT THESIS

- Opportunity to invest in three businesses at inflection points for accelerated growth with clearly identified catalysts.
- Large addressable markets where there is a strong ability to capitalize on secular changes.
- Attractive risk-return asymmetry through security structuring, asset-level coverage.
 and equity upside via warrants and conversion rights.

PES FIT & TRANSACTION STRUCTURE

- An investment in three select, seasoned, performing platform companies with a need for capital to take advantage of transformational growth opportunities.
- An opportunity to invest in select companies backed by a strong sponsor with a successful track record in the lower middle market.
- Combination of debt and equity-like instruments benefitting from structural seniority and meaningful collateral basis, thereby providing DWS capital with strong risk/return asymmetries and a greater degree of visibility for "in the money" capital.

PAYOUT ANALYSIS BASED ON CHANGES IN ENTERPRISE VALUE



^{* \$3.4}m of Conquest investment is non-convertible subordinated debt: 10% cash interest, 4% PIK

PACIFIC GROWTH INVESTORS

//DWS

Structured equity investments into 3 companies

Progress Since Entry



Sandel Avionics (52% of NAV1)

- Lack of funding has slowed down the final FAA certification of Avilon.
- Sandel was unable to sell its legacy product lines in H2 2019 due to a stockout issue.



Emerge Diagnostics (19% of NAV¹)

- Continued to experience positive tailwinds with new and existing customers in 2019, some of which will only come online in 2020.
- Continued buildout of senior management team through new CFO and VP of Sales.
- New senior credit facility put in place to support growing new client implementation.



Conquest Firespray (28% of NAV1)

- Tailwinds remain strong, however certain projects were delayed from 2019 to 2020.
- New Chief Revenue Officer put in place who will focus on building out the East Coast and Mid-Atlantic efforts.

RECENT DEVELOPMENTS AND COVID IMPACT

Positives:

- Sandel Avionics in negotiations to sell a perpetual license on a legacy product to a large avionics group. This would create a partial liquidity event for PES and bring cash into the company.
- Evercore is representing Sandel Avionics in potential discussions around a JV for Sandel's Avilon digital cockpit system. Evercore has indicated a potential pre-money valuation for Sandel of \$80 million.
- Conquest had strong months in January and February and a record backlog going into March. The Company continues to receive new orders for its product despite the operational challenges presented by the Covid crisis.
- Emerge has seen continued strong demand for its product in recent months prior to Covid and is currently piloting a telehealth offering.

Challenges:

- Sandel had been in the process of raising capital from 3rd parties when the crisis hit. PES injected a small amount of capital in March. Further capital will need to be raised to see it through to a potential JV.
- Conquest has had to close some of its manufacturing facilities due to state shut downs in the Us and has furloughed some staff. PES elected to inject a small amount of capital into the business in April.
- Emerge has clients in the transportation and distribution sectors and has seen some weakening in revenues in April.

CAMBRIDGE INNOVATION CAPITAL



U.K. healthcare and technology portfolio

Transaction Summary



| Sector | Health Care | | | |
|------------------|---|--|--|--|
| Asset Type | VC & Lifesciences | | | |
| Country | United Kingdom | | | |
| GP | Cambridge Innovation Capital | | | |
| Sourcing | Advised | | | |
| Transaction Type | Capital for Growth | | | |
| Description | Growth capital investment in seasoned technology and healthcare portfolio | | | |

Deal Statistics

| Transaction Date | November 2018 | | |
|-----------------------|--------------------------|--|--|
| Commitment | £15.0m | | |
| Capital Called | £8.1m as of Dec 31, 2019 | | |
| Target Returns to PES | 2.3x MOIC / 28% IRR | | |
| TV/TC as at Dec 2019 | 1.33x | | |

DWS has prepared, where applicable, the material in this section based on data provided third parties. DWS does not guarantee the accuracy and completeness of this information. There is no assurance that investment objectives will be achieved. For illustrative purposes only. Past performance is not a reliable indicator of future returns. No assurance can be given that any forecast, target or opinion will materialize. Due to various risks, uncertainties and assumptions made in our analysis, actual events or results or the actual performance of the markets covered may differ materially from those described. * Target return expectations for investments have been formed through historical operating and valuation performance coupled with forward looking expectations from the financial sponsor, company management, and PES's view of underlying company performance over our hold period. Please refer to Risk Factors in the Investment Memorandum for important information.


INVESTMENT THESIS

- Opportunity to invest in a portfolio of high quality assets at an inflection point in their development and with multiple paths to meet target returns. DWS underwritten returns represent a 50% haircut to the sponsor's forecasts
- Key portfolio companies operating in large and growing markets with innovative technologies and the potential to have highly disruptive impacts on industry incumbents

PES FIT & TRANSACTION ALIGNMENT

- CIC supports the PES core thesis of identifying high quality private market companies backed by strong sponsors at inflection points with clear pathways to additional value creation
- Strong alignment with the cornerstone sponsor, Cambridge Innovation Capital
- Investment seeks to enhance the value of the portfolio by providing followon capital for key growth initiatives
- Investment facilitated the restructuring of the vehicle to operate like a PE fund providing full economic rights before the commitment is funded

CAMBRIDGE INNOVATION CAPITAL PORTFOLIO OVERVIEW¹



CAMBRIDGE INNOVATION CAPITAL

U.K. healthcare and technology portfolio


// DWS

Progress Since Entry



CMR Surgical¹

- Secured regulatory approval in Europe & Australia
- Raised £195m Series C round at substantial step-up in valuation,
- Completed initial commercial sales with growing pipeline



PragmatIC Printing¹

- Improved production yields & built order book of over >20M units
- Working on program to track diagnostic samples for the U.K. NHS which performs 1.1bn tests per year



Bicycle Therapeutics¹

- Completed IPO on NASDAQ
- Made progress on numerous clinical trials
- Signed strategic partnerships with AstraZeneca & Genentech



Congenica¹

- Won multi-year exclusive partnership to provide diagnostic decision support software to the NHS Genomic Medicine Service
- Supporting study of genome of 35,000 people impacted by Covid



Inivata¹

- Secured regulatory approval and reimbursement in U.S.; first company to achieve this after Guardant (NASDAQ: GH)
- Commercialization slower than expected due to intense competition. CIC took conservative write-down in H2 2019.
- Company has announced \$25m investment from NeoGenomics at a material step-up to Dec-19 valuation.
- NeoGenomics has option to acquire Inivata.

RECENT DEVELOPMENTS AND COVID IMPACT

Positives:

- Portfolio broadly prepared for shock, with cash reserves at companies and at CIC level.
- Laboratory work continues as it is an essential service.
- UK government has generous furlough program and has recently launched the Future Fund to issue matching convertible loans for companies facing financing constraints due to Covid-19.
- Sense Biodetection is partnering with Phillips-Medisize to launch instrument-free molecular test for Covid-19.
- Bicycle & Inivata should be marked up from Dec-2019 figures due to increase in Bicycle share price and recent third party investment in Inivata.

Challenges:

- Delays in R&D, clinical trials and regulatory approvals.
- Companies planning to raise capital in 2020 will need insider rounds.
- Customers may delay purchase decisions through the crisis.




PES HIGH PRIORITY PIPELINE



DWS PE Team has a robust set of actionable opportunities

| Project | Transaction Description | Sponsor | Size (USD \$m) | Geography | Source |
|---------|--|---|-------------------|-----------|-------------|
| Flex | Opportunity to provide growth capital for add-ons and partial liquidity to an operator of urgent care clinics. | U.S. healthcare- focused mid-market sponsor | \$100m | USA | Proprietary |
| Emperor | Opportunity to fund an add-on acquisition and provide growth capital to an operator of value-based cancer treatment centres | U.S. lower mid-market sponsor | \$10m | USA | Proprietary |
| Woods | Opportunity to finance add-on in European campsite operator | Nordic mid-market sponsor | \$20m | Europe | Proprietary |
| Clouds | Opportunity to provide partial liquidity at an attractive valuation for a women's apparel brand with strong customer base affinity | U.S. mid-market sponsor | \$25m | USA | Proprietary |
| Mane | Opportunity to provide M&A / add-on capital to global brand licensing company | Global mid-market sponsor | \$20m | Global | Proprietary |
| Garden | Opportunity to provide follow-on capital to several portfolio companies | U.K. mid-market sponsor | \$80m | Europe | Proprietary |

Source: DWS RIMS System for PE investments as at May 2020. Illustrative and may not be comparable in type, quality or performance to the investments in a Fund. There is no guarantee that investments or similar investments will be made. Available USD is rounded to nearest \$10m. Above reflects active diligence, high-priority pipeline. Full pipeline includes additional early-stage opportunities currently under review.









Mark McDonald Global Head

Mark McDonald is Global Head of DWS Private Equity responsible for all aspects of the private equity business including business development, investments and fundraising and also sits on the firm's Executive Committee for Alternatives. He joined DWS in 2017 from Credit Suisse, where he was global head of secondary advisory and won several awards for creating and leading innovative and solutions driven secondaries transactions. Mark has over 22 years of experience, including 18 years in private equity with Barclays Capital, 3i, Keyhaven Capital Partners and Pomona Capital; where he led EMEA and sat on the boards of various underlying investment partnerships. He holds an MBA from SDA Bocconi and a BA (Honors) degree in Economics and Politics from the University of Leeds.



Daniel Green Head of EMEA

Daniel Green is a Managing Director of DWS Private Equity with responsibility for the activities of the business in EMEA. Daniel has 22 years experience in finance, 19 years of which in private equity. Prior to joining DWS Private Equity, Daniel was a Senior Director at Meketa Investment Group where he led EMEA investment activities across private equity and real assets. Previously he spent 13 years with Greenpark Capital, a UK-headquartered secondaries private equity fund manager with \$2 billion of commitments, rising to the position of Chief Investment Officer. He started his career at PriceWaterhouseCoopers and holds a Masters in Modern Languages (French and Spanish) from the University of St Andrews.



Kumber HusainHead of Americas

Kumber Husain joined DWS Private Equity in 2018 with over 17 years total experience, mainly in private equity, predominantly in secondaries. Kumber is a highly experienced transaction professional with over \$1.5 billion deployed across 25 separate secondaries and private market transactions. Kumber was formerly Portfolio Manager and Investment Committee member at Morgan Stanley Alternative Investment Partners, a leading global private market platform with over \$12 billion of assets under management. He previously held the position of Senior Vice President at WP Global Partners, a \$3 billion private markets platform focused on primaries, secondaries and direct/co-investments. Prior to that he worked at Swiss Re in their corporate development group and also played a leading role on executing a structured secondary sale of 40 legacy LP interests. He holds an MSc from London School of Economics and a BA in Political Sciences from George Washington University.

Team biographies





Rodrigo Patiño Senior Investment Team

Rodrigo is a Portfolio Manager with over 11 years of investment experience, executing more than two dozen direct and secondary transactions in fifteen countries. Prior to joining DWS Private Equity in 2016, Rodrigo was a Vice President in the Direct Investment team at HarbourVest Partners, a private markets specialist with over \$50 billion in assets under management. He joined HarbourVest from Goldman Sachs in New York, where he spent two years evaluating secondary, direct and partnership investments in their Private Equity Group. Rodrigo received an MBA (Honors) from The Wharton School of the University of Pennsylvania and a BS in Economics (Cum Laude). Rodrigo speaks Spanish, French, and Portuguese.



Jordan Sawkin Senior Investment Team

Jordan is a Portfolio Manager with 11 years of PE experience in the US and Europe, executing over 30 transactions for \$1 billion in invested capital curing that time. Prior to joining the firm in 2016, Jordan was a Senior Associate on the investment team in London and New York at Grosvenor Capital Management (GCM), a \$50 billion alternative asset management firm. During his time there, his investment responsibilities included direct, co-investments and secondaries transactions across PE and energy/infrastructure asset classes. Jordan also played a critical role in client engagement while at GCM, having focused on building managed PE programs for two of the largest US pension plans. Prior to joining GCM, he was an investment analyst within Credit Suisse's \$23 billion private equity group in New York. Jordan holds a BA in History from The College of Wooster.



Ian Hall Investment Team

lan joined DWS Private Equity in 2019 with 6 years of private markets experience in both the US and Europe, having completed 17 transactions for more than \$550 million of invested capital during that time. Previously, lan was an Associate at New 2ND Capital, a special situations private equity firm focused on bespoke secondary solutions for the US lower middle-market. He joined New 2ND from Morgan Stanley Alternative Investment Partners, where he assisted in the sourcing, diligence and execution of structured secondary solutions as a member of their Private Equity Secondaries investment team. Ian began his career as an Investment Analyst at Northwestern Mutual Capital, evaluating private market transactions for the team's \$7 billion private equity portfolio, including direct equity co-investments, mezzanine debt financings, unitranche facilities, and other securities. Ian holds a BBA from the University of Notre Dame.

Team biographies





Alex Polis
Investment Team

Alex joined DWS Private Equity in 2018 with 5 years of Investment Banking advisory experience, completing over \$2 billion of transactions with both corporate and PE clients. Previously, Alex was an Associate and Analyst in the EMEA Technology, Media and Telecommunications Investment Banking team at Jefferies in London across all product areas. During his time there, he focused on M&A, Equity and Debt transactions. Prior to joining Jefferies, he was an Analyst at Lepe Partners, an independent merchant bank focused on the media, consumer and technology sectors with co-investing capabilities. Alex speaks Polish and holds an MSc in Finance from IE Business School and a BA in Economics from McGill University.



Anamica Broetz Head of Business Development & Strategy

Anamica Broetz leads the Business Development function for DWS Private Equity, working alongside senior management to develop the team's business plans, deal origination and marketing strategy. She liaises with DWS's distribution, product development and legal teams to manage the investment team's processes for fund offerings (including co-investments) and structuring. She leads all aspects of limited partner due diligence to drive successful conversions during fundraising. Anamica brings over 22 years of experience in equity research, investment banking and PE at Deutsche Bank M&A, Dresdner Kleinwort Wasserstein, Flemings and Peregrine Capital prior to joining DWS Private Equity in 2010. She speaks German and holds a Masters in Finance from Delhi University and a BA (Honors) degree in Economics from Shri Ram College of Commerce of Delhi University.



Audie Apple Senior Americas Coverage

Audie leads the client coverage and investor relations efforts for DWS Private Equity in the Americas. In his role he works closely with the investment team in sourcing and underwriting fund investment opportunities and collaborating with investors in the syndication of co-investment opportunities. Audie brings over 20 years of investment experience in a variety of roles spanning portfolio management, marketing, sales and multiple leadership roles managing teams focused in the U.S. as well as globally. Audie has extensive public speaking experience having addressed audiences of institutional investors as well as investment management and research professionals around the world. Audie speaks Spanish and Portuguese and holds a Masters (Honors) from Ohio University and a BBA (Honors) from Millsaps College.







Neel Mehta Chief Financial Officer

Neel Mehta leads the finance and accounting function for DWS Private Equity, working alongside the senior investment team to drive growth and shaping financial best practice. He joined DWS Private Equity in 2018 from Mayfair Equity Partners, where he built and managed the accounting and finance function, including fund structuring and regulatory planning. Prior to this he was the Finance Manager at Keyhaven Capital Partners where he transformed the entire back office operations, systems and processes. Neel has over 12 years of experience in PE and joined the business with a thorough understanding of the PE life cycle, including fundraising and limited partner due diligence. He is a member of the BVCA Regulatory Committee, a Fellow of the Association of Chartered Certified Accountants and holds a BA (Honors) in International Accounting and Finance from the University of Brighton.



Freddy Taggart Chief Operating Officer

Freddy is the COO for DWS's Infrastructure, Private Equity and Hedge Fund businesses. As COO, he is responsible for all operational aspects of the business, facilitating the business' strategic goals, driving growth and managing the business' P&L. He joined DWS in 2007 and has 23 years of experience in financial services, working in corporate finance at UBS, financial control at Bear Stearns and Group Audit at HSBC prior to joining DWS. He holds a BA (Honors) from The University of Manchester and started his career at Mazars, where he qualified as a Chartered Accountant.



RISK CONSIDERATIONS



Capital at Risk

The investments described herein are not capital protected nor are they capital guaranteed. Investors should be prepared and able to sustain losses of the capital invested, up to a total loss. The value of an investment may go down as well as up.

Private Equity

Private Equity strategies are complex and may be suitable only for very sophisticated investors who, based on their own investment expertise or that of their financial advisor, understand its strategy, characteristics and risks. Investments in private equity strategies are speculative and involve a high degree of risk. Investors should be aware of the attendant risks including, but not limited to the potential for higher fees and lack of strategy transparency. Private Equity strategies may employ a single strategy, which may result in a lack of diversification, and consequently higher risk.

Forecasts and Projections

No assurance can be given that any investment objective, expected returns or structure described herein will be achieved or yield favourable investment results, or that the investor will receive a return of all or part of their investment.

Past performance or any prediction or forecast is not indicative of future results.

Complex nature of due diligence and valuation process

The investment described may lack the benefit of financial statements and periodic company updates. This may affect its ability to conduct fundamental due diligence. In addition, the absence of transparent data and lack of publicly available information may impact the accuracy with which Investments can be valued. The valuation methodology and timing between the different investments may also vary, impacting valuation analysis.

Lack of Liquidity

The underlying investments are likely to be illiquid and lacking a public market. The return of capital on investments and the realisation of gains, if any, will generally only occur upon the partial or total disposition of an investment. Political and regulatory restraints could adversely affect the favourable sale or purchase of investments. The sale of investments may require a lengthy time period or result in distributions in kind.

Reliance on Management of Portfolio Companies

The underlying funds and portfolio companies rely on key personnel. There can be no assurance that they will continue to devote sufficient time and attention to the portfolio companies.



FOR PROFESSIONAL CLIENTS ONLY

Issued and approved by DWS Alternatives Global Limited of Winchester House, 1 Great Winchester Street, London, EC2N 2DB, authorised and regulated by the Financial Conduct Authority ("FCA"). DWS Alternatives Global Limited is also registered with the U.S. Securities and Exchange Commission under the Investment Advisers Act 1940 (the "Advisers Act"), however it complies with the Advisers Act only with respect to US clients.

This document is a "non-retail communication" within the meaning of the FCA's Rules and is directed only at persons satisfying the FCA's client categorisation criteria for an eligible counterparty or a professional client. This document may not be reproduced or circulated without written consent of the issuer.

This document is intended for discussion purposes only and does not create any legally binding obligations on the part of DWS Group GmbH & Co. KGaA and/or its affiliates ("DWS"). Without limitation, this document does not constitute investment advice or a recommendation or an offer or solicitation and is not the basis for any contract to purchase or sell any security or other instrument, or for DWS to enter into or arrange any type of transaction as a consequence of any information contained herein. The information contained in this document is based on material we believe to be reliable; however, we do not represent that it is accurate, current, complete, or error free. Past performance is not a guarantee of future results. Any forecasts, assumptions and estimates provided herein are based upon our opinion of the market as at this date and are subject to change. Any prediction, projection or forecast is not necessarily indicative of the future or likely performance. Investments are subject to risks, including possible loss of principal amount invested.

When making an investment decision, potential investors should rely solely on the final documentation relating to the investment or service and not the information contained herein. The investments or services mentioned herein may not be appropriate for all investors and before entering into any transaction you should take steps to ensure that you fully understand the transaction and the possible risks and benefits of entering into such a transaction and have made an independent assessment of the appropriateness of the transaction. You should also consider seeking advice from your own advisers in making this assessment. If you decide to enter into a transaction with us you do so in reliance on your own judgment.

DWS specifically disclaims all liability for any direct, indirect, consequential or other losses or damages including loss of profits incurred by you or any third party that may arise from any reliance on this document or for the reliability, accuracy, completeness or timeliness thereof.

Any reference to "DWS", shall, unless otherwise required by the context, be understood as a reference to asset management activities conducted by DWS Group GmbH & Co. KGaA and/or any of its affiliates. Clients will be provided DWS products or services by one or more legal entities that will be identified to clients pursuant to the contracts, agreements, offering materials or other documentation relevant to such products or services.

© DWS Alternatives Global Limited 2020. All rights reserved.

(UKC: JB 28/05/2020 / BC: CRC# 076186 2.2)



Austria

DWS International GmbH, Vienna Branch, with its registered office in Vienna, Republic of Austria, registered with the companies register of the Vienna Commercial Court under FN 490436 f as an Austrian branch of DWS International GmbH with its registered office in Frankfurt am Main, Federal Republic of Germany, registered with the commercial register of the Frankfurt am Main District Court under HRB 23891. UID: ATU73270417. Deutsche Bank Group.

The information contained in this document is exclusively for fund and asset managers, financial advisors and other professional clients (according to the Austrian Securities Supervision Act (Wertpapieraufsichtsgesetz 2018)) and may not be passed on electronically, by fax, by mail, by delivery of copies or by any other way to third parties. The information in this document does not constitute investment advice or an investment recommendation and is only a brief summary of key aspects of the funds.

The information contained in this document and other documents connected with this document is not an offer to sell or a solicitation of an offer to purchase or an exchange of fund units, or a prospectus within the meaning of the Austrian Capital Markets Act (Kapitalmarktgesetz – KMG), the Austrian Stock Exchange Act 2018 (Börsegesetz 2018 – BörseG 2018) or the Austrian Investment Fund Act (Investmentfondsgesetz 2011 – InvFG 2011), and this information was therefore not prepared, reviewed, approved, or published in accordance with these provisions.

Investment decisions should be made exclusively on the basis of the key investor information document and the published prospectus, as supplemented by the latest audited annual report and the latest semi-annual report, if this report is more recent than the last annual report, as well as any supplementary offer documents. Only these documents are binding.

The documents stated above are available in German free of charge in electronic or printed format from your financial advisor, from DWS International GmbH Vienna Branch, Fleischmarkt 1, A 1010 Vienna, on the www.dws.at website, from DWS Investment GmbH, Mainzer Landstraße 11-17, D-60327 Frankfurt am Main, and, for Luxembourg funds, from DWS Investment S.A., 2 Boulevard Konrad Adenauer, L-1115 Luxembourg.

The prospectus contains detailed risk information. Any views expressed in this document reflect the current assessment of DWS Investments, which may change without notice.

Calculation of the performance follows the BVI method (gross performance based).

The gross performance (BVI method) includes all costs incurred at the fund level, the net performance also includes the sales charge; additional costs may be incurred at the investor level (e.g. custody costs, fees, commissions or other expenses). Since the sales charge is only levied in the first year, the net/gross amount shown is different only in this year.

Past performance is not a reliable indicator of the future performance of a fund.

For further information on taxation, please refer to the full prospectus. It is recommended that persons who purchase, hold, or intend to dispose of investment fund units seek the advice of an accounting professional regarding the individual tax consequences of the purchase, holding, or disposal of the investment fund units described in this document. It should be noted that the tax advice depends on the personal situation of the individual investor and that the tax advice regarding financial products may change in future (also retrospectively) as a result of decisions by the tax authorities and court rulings.

The information in this document is marketing information, which has been provided exclusively for informational and advertising purposes. The information provided is not a financial analysis and is therefore subject neither to the statutory requirements to promote the independence of financial analyses nor to the prohibition on trading following the dissemination of financial analyses.

The units issued under the funds described in this document may only be offered for sale or sold in jurisdictions in which such an offer or purchase is permitted.



Austria (Cont'd)

For professional investors only. Not for distribution to retail clients or the general public.

No part of this material may, without DWS Investment GmbH's ("DWS") prior written consent, be (i) copied, photocopied or duplicated in any form, by any means, or (ii) distributed to retail clients or the general public.

This document is strictly for information purposes and should not be considered as investment advice or an offer or solicitation to deal in any of the investments mentioned herein, or as a prospectus within the meaning of the Austrian Capital Markets Act (Kapitalmarktgesetz – KMG), the Austrian Stock Exchange Act (Börsegesetz 2018 – BörseG) or the Austrian Investment Fund Act (Investmentfondsgesetz 2011 – InvFG 2011), and this information was therefore not prepared, reviewed, approved, or published in accordance with these provisions. This document does not constitute investment advice or investment research as defined under EU Directive 2014/65/EU, the Commission Delegated Regulation (EU) 2017/565 or of laws or regulations implementing any of them in the Member States. The information in this document is marketing information which has been provided exclusively for information and advertising purposes.

Any research or analysis used in the preparation of this document has been procured by DWS for its own use and DWS may have used it for its own purposes. Some of the information in this document may contain projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies. These statements are only a prognosis and actual events or results may differ materially. Any information relating to past performance is not a reliable indicator of the future results of an investment. Any views expressed in this document reflect the current assessment of DWS, which may change without notice. Any addressee of this document must make their own assessment of the relevance, accuracy and adequacy of the information contained in this document and such independent investigations as they consider necessary or appropriate for the purpose of such assessment. Investment decisions should be made, as applicable, on the basis of the key investor information document, the investor information document pursuant to Art 23 of Directive 2011/61/EU and/or the published prospectus, as supplemented by the latest audited (semi-)annual report and/or any supplementary offer documents of any investments mentioned herein. Only these documents are binding. Any opinions or assessments contained in this document are of a general nature and are not to be relied on by any person as investment advice.

Belgium

The information contained herein is only intended for and must only be distributed to institutional and/or professional investors (as defined in the Royal Decree dated 19 December 2017 implementing MiFID directive). In reviewing this presentation you confirm that you are such an institutional or professional investor. When making an investment decision, potential investors should rely solely on the final legal documentation (including the prospectus) relating to the investment or service product: and not the information contained in the present document herein is purely illustrative, educational or informative. The investments or services products mentioned herein may not be adequate or appropriate for all investors and before entering into any transaction you should take steps to ensure that you fully understand the transaction and have made an independent assessment of the suitability or appropriateness of the transaction in the light of your own objectives and circumstances, including the possible risks and benefits of entering into such transaction. You should also consider seeking advice from your own advisers (including tax advisers) in making this assessment. If you decide to enter into a transaction with us you do so in reliance on your own judgment.



China

This Document has been prepared by DWS Investments UK Limited and is intended for the exclusive use by the intended recipients in the People's Republic of China ("PRC"), which, for the purpose of this Document shall exclude Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan to whom DWS Investments UK Limited has directly distributed this Document. Information contained herein may not be wholly or partially reproduced, distributed, circulated, disseminated or published in any form by any recipient for any purpose without the prior written consent of DWS Investments UK Limited. Although information contained herein is believed to be materially correct, DWS Investments UK Limited does not make any representation or warranty, express or implied, to the accuracy, completeness, correctness, usefulness or adequacy of any of the information provided. Neither DWS Investments UK Limited, its affiliates, nor any of their directors, officers, employees, representatives, agents, service providers or professional advisers, successors and assigns shall assume any liability or responsibility for any direct or indirect loss or damage or any other consequence of any person/entity acting or not acting in reliance on the information contained herein. This Document is for informational purposes only and does not constitute a recommendation, professional advice, solicitation for offer or offer by DWS Investments UK Limited to subscribe, purchase or sell any security or interest of any pooled products in PRC, nor shall it be construed as any undertaking of DWS Investments UK Limited to complete any transaction in relation to any pooled products and services. This Document has not been and will not be approved by any PRC governmental or regulatory authority. Generally, this Document shall be distributed to specific entities on a private basis and may solely be used by such specific entities who satisfy themselves as to the full compliance of the applicable PRC laws and regulations with all necessar

France

The offer of the Interests has not been notified to the French authority supervising the financial markets, the autorité des marchés financiers ("AMF") pursuant to Article L.412-1 of the French financial and monetary code, nor has this Memorandum nor any other offering material relating to the Interests been submitted to the clearance procedures of the AMF or to the competent authority of another member state of the European Economic Area and subsequently notified to the AMF. The Interests have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this Memorandum nor any other offering material relating to the Interests has been or will be: released, issued, distributed or caused to be released, issued or distributed to the public in France; or used in connection with any offer for subscription or sale of the Interests to the public in France. Such offers, sales and distributions will be made in France only: to qualified investors (investisseurs qualifiés) and/or to (cercle restreint d'investisseurs), in each case investing for their own account, all as defined in, and in accordance with, articles L.411-2, D.411-1, D.734-1, D.744-1, D.754-1 and D.764-1 of the French Code monétaire et financier ("CMF"); or to investment services providers authorised to engage in portfolio management on behalf of third parties; or in a transaction that, in accordance with article L.411-2-II-1°-or-2°-or 3° of the CMF and article 211-2 of the Règlement Général of the AMF, does not constitute a public offer. The Interests may be resold directly or indirectly to the public in France, only in compliance with articles L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the CMF. This Memorandum and any other offering materials are strictly confidential and may not be distributed to any person or entity other than the recipients hereof.

Germany

DWS is the brand name under which DWS Group GmbH & Co. KGaA and its subsidiaries operate their business activities. Clients will be provided DWS products or services by one or more legal entities that will be identified to clients pursuant to the contracts, agreements, offering materials or other documentation relevant to such products or services. The information contained in this document does not constitute investment advice. All statements of opinion reflect the current assessment of DWS Investment GmbH and are subject to change without notice.

Forecasts are not a reliable indicator of future performance. Forecasts are based on assumptions, estimates, opinions and hypothetical performance analysis, therefore actual results may vary, perhaps materially, from the results contained here. Past performance, [actual or simulated], is not a reliable indication of future performance. The calculation of performance uses the BVI (Bundesverband Investment and Asset Management) method and therefore does not take the Upfront Sales Charge into account. Individual costs such as fees and other charges, which would have a negative impact on the performance, have not been taken into account. The information contained in this document does not constitute a financial analysis but qualifies as marketing communication. This marketing communication is neither subject to all legal provisions ensuring the impartiality of financial analysis nor to any prohibition on trading prior to the publication of financial analyses. This document and the information contained herein may only be distributed and published in jurisdictions in which such distribution and publication is permissible in accordance with applicable law in those jurisdictions. DWS Investment GmbH. As of: 2020



Hong Kong

The fund is not authorized by the Securities and Futures Commission in Hong Kong, and is not available for subscriptions by investors in Hong Kong, other than to professional investors as stipulated in the Securities and Futures Ordinance. This document has not been reviewed by the Securities and Futures Commission in Hong Kong.

Investment involves risk, including possible loss of principal amount invested. Past performance information presented is not indication of future results. The investment returns are denominated in share class dealing currency, which may be a foreign currency. The US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / foreign currency exchange rates. Investors should read the offering documents for further details, including the risk factors before investing. This document is for information purposes only and is not the basis for any contract to deal in any security or instrument, or for DWS Group GmbH & Co. KGaA or its affiliates ("DWS") to enter into or arrange any type of transaction as a consequence of any information contained here. This document does not constitute an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. You are advised to consult your financial adviser before making any investment decision. Although the information provided by third party was compiled from sources believed to be reliable, no liability for any error or omissions is acceptable by DWS, its approved distributors, or its affiliates or any of its directors or employee. The information and opinions contained herein is for general reference only and may change without notice, and should not be relied upon for any investment decision. All third party data (such as MSCI, S&P, Dow Jones, FTSE, Bank of America Merrill Lynch, Factset & Bloomberg) are copyrighted by and proprietary to the provider.

This document may include forward looking statements. The forward looking statements expressed constitute the author's judgment as of the date of this material. Forward looking statements involves significant elements of subjective judgments and analyses and changes thereto and / or consideration of different or additional factors could have a material impact on the results indicated. No representation or warranty is made by DWS as to the reasonableness or completeness of such forward looking statement or to any other financial information contained herein. This document is issued by DWS Investments Hong Kong Limited ("DWS HK") and is the property and copyright of DWS HK. This document may not be reproduced or circulated without DWS HK's written consent. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries. All rights reserved. © 2020 DWS Investments Hong Kong Limited

Indonesia

This Document does not constitute an offer to sell nor a solicitation to buy securities in Indonesia.

Ireland

The distribution of this Memorandum and the offering or purchase of Interests is restricted to the individual to whom it is addressed. Accordingly, it may not be reproduced in whole or in part, nor may its contents be distributed in writing or orally to any third party and it may be read solely by the person to whom it is addressed and his/her professional advisers.

Interests in the Fund will not be offered or sold by any person: otherwise than in conformity with the provisions of the European Communities (Markets in Financial Instruments) Regulations 2007, as amended; or otherwise than in a manner that does not constitute an offer for sale to the public within the meaning of Section 9 of the Unit Trust Act, 1990; or in any way which would require the publication of a prospectus under the Investment Funds, Companies and Miscellaneous Provisions Act, 2005, as amended and any regulations adopted pursuant thereto; or in any country or jurisdiction including Ireland except in all circumstances that will result in compliance with all applicable laws and regulations in such country or jurisdiction. Interests in the Fund will not in any event be marketed in Ireland except in accordance with the requirements of the Central Bank of Ireland.



Israel

Deutsche Alternative Asset Management ("DB") is not a holder of a license granted in Israel pursuant to the Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 1995 ("the Investment Law") and does not hold the insurance coverage required of a licensee pursuant to the Investment Law.

This document and any information provided by DB in relation to the contents thereof will not under any circumstances be deemed investment "advice" (as such term is defined in the Investment Law). DB is acting as a "marketing agent" (as such term is defined in the Investment Law) and any use of the word "advice" or any derivative thereof in this document should not be taken to mean that DB is offering "advice" as such term is defined in the Investment Law.

The transaction or investment described in this document ("the investment") may have been produced or issued by DB or by a third party. In either case, in the event that a client of DB enters into the investment, DB may receive a financial benefit that is separate from, and in addition to, any fee, commission or other payment (if any) made to it by the client.

DB has chosen to market the investment because DB receives certain benefits when one of its clients invests in the investment. Other similar transactions or investment opportunities to which DB has no connection, may also be available however DB has chosen not to market these.

This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent.

This document has been prepared exclusively for Qualified Clients as such term is defined in the First Schedule to the Investment Law and/or the First Schedule of the Israel Securities Law, 5728-1968 ("Securities Law"). As a prerequisite to the receipt of a copy of this document a recipient may be required to provide confirmation and evidence that it is a Qualified Client.

This document has not been approved by the Israeli Securities Authority and will not constitute "an offer to the public" under sections 15 and 15a of the Securities Law or section 25 of the Joint Investment Trusts Law, 5754-1994.

Italy

This document does not constitute a public offering of financial instruments pursuant to art. 1, comma 1, let. t) of Legislative Decree. n. 58/98 and thus is not subject to art. 101 of the same regulation. The information here reported refers to a financial product that has not been authorized by the relevant Regulatory Authorities for distribution in Italy nor has a notification process amongst EU Regulatory Authorities taken place. As a result, the information here reported does not constitute and should not be intended, under any circumstance, as the provision of investment advisory, nor research in financial instruments nor financial analysis nor any other form of general recommendation related to transactions in financial products.Last, this document and the information provided herein do not create any legal binding obligation between the parties.

Japan

This document is prepared by DWS Alternatives Global Limited and is distributed in Japan by DWS Investments Japan Limited. Please contact the responsible employee of DWS Investments Japan Limited in case you have any question on this document because DWS Investments Japan Limited serves as contacts for the product or service described in this document. This document is for distribution to Professional Investors only under the Financial Instruments and Exchange Law.



Kazakhstan

DWS Alternatives Global Limited is an entity registered and operating under the laws of the United Kingdom. The product is marketed and offered by DWS Alternatives Global Limited on a cross-border basis from the United Kingdom only; and the Private Equity Solutions fund is registered under the legislation of Luxembourg and will not be and are not intended to be registered or offered in or from the territory of the Republic of Kazakhstan. An investment into the Private Equity Solutions fund by a Kazakhstan resident may be subject to certain restrictions, limitations and requirements as imposed under Kazakhstan law or applicable under any internal document of the investor, including inter alia limitation of the investment capacity. A Kazakhstan resident making an investment into the Private Equity Solutions fund shall ensure that its investment will be in strict compliance with any of such restrictions, limitations and requirements as established under Kazakhstan law or any applicable internal document.

Luxembourg

Neither the Prospectus nor any other document or material in relation to the Funds has been lodged, filed or registered with or otherwise approved by the Commission de surveillance du secteur financier (CSSF) or the Luxembourg Stock Exchange. The Funds may not be offered or sold in the Grand-Duchy of Luxembourg, except for Shares which are offered in circumstances that do not require the approval of a prospectus by the Luxembourg financial regulatory authority in accordance with the Law of December 17, 2010 as amended on undertakings for collective investment. The Funds are offered to a restricted circle of sophisticated persons previously known to DB AG or its subsidiaries, in all cases under circumstances designed to preclude a distribution that would be other than a private placement. This Presentation may not be reproduced or used for any purpose, or provided to any person other than those to whom copies have been sent.

Malaysia

As the approval of the Malaysian Securities Commission pursuant to section 212 of the Malaysian Capital Markets and Services Act 2007 has not been / will not be obtained, to Products hereunder are not being and will not be deemed to be issued, made available, offered for subscription or purchase in Malaysia, and neither this presentation nor any document or other material in connection therewith should be distributed, caused to be distributed or circulated in Malaysia, to individuals or other legal entities who fall under paragraphs 8, 9, 11, 12 or 13 of Schedule 6 to the Capital Markets and Services Act 2007.

Netherlands

DWS is the brand name under which DWS Group GmbH & Co KGaA and its subsidiaries operate their business activities. Clients will be provided DWS products or services by one or more legal entities that will be identified to clients pursuant to the contracts, agreements, offering materials or other documentation relevant to such products and services.

This document has been prepared without consideration of the investment needs, objectives or financial circumstances of any investor. Before making an investment decision, investors need to consider, with or without the assistance of an investment adviser, whether the investments and strategies described or provided by DWS, are appropriate, in light of their particular investment needs, objectives and financial circumstances. Furthermore, this document is for information/discussion purposes only and does not constitute an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice.

DWS does not give tax or legal advice. Investors should seek advice from their own tax experts and lawyers, in considering investments and strategies suggested by DWS. Investments with DWS are not guaranteed, unless specified. Unless notified to the contrary in a particular case, investment instruments are not insured by the Deposit Guarantee Scheme or any other governmental entity, and are not guaranteed by or obligations of DWS Group GmbH & Co or its subsidiaries.



Netherlands (Cont'd)

Although information in this document has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness, and it should not be relied upon as such. All opinions and estimates herein, including forecast returns, reflect our judgment on the date of this report and are subject to change without notice and involve a number of assumptions which may not prove valid. Investments are subject to various risks, including market fluctuations, regulatory change, counterparty risk, possible delays in repayment and loss of income and principal invested. The value of investments can fall as well as rise and you may not recover the amount originally invested at any point in time. Furthermore, substantial fluctuations of the value of the investment are possible even over short periods of time.

This publication contains forward looking statements. Forward looking statements include, but are not limited to assumptions, estimates, projections, opinions, models and hypothetical performance analysis. The forward looking statements expressed constitute the author's judgment as of the date of this material. Forward looking statements involve significant elements of subjective judgments and analyses and changes thereto and/or consideration of different or additional factors could have a material impact on the results indicated. Therefore, actual results may vary, perhaps materially, from the results contained herein. No representation or warranty is made by DWS as to the reasonableness or completeness of such forward looking statements or to any other financial information contained herein. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Offering Documents. When making an investment decision, you should rely on the final documentation relating to the transaction and not the summary contained herein.

This document may not be reproduced or circulated without our written authority. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries, including the United States. This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, including the United States, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject DWS to any registration or licensing requirement within such jurisdiction not currently met within such jurisdiction. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions. Past performance is no guarantee of future results; nothing contained herein shall constitute any representation or warranty as to future performance.

Philippines

Any person claiming an exemption under Section 10.1 of the Securities Regulation Code ("SRC") (or the exempt transactions) must provide to any party to whom it offers or sells securities in reliance on such exemption a written disclosure containing the following information:

- (1) The specific provision of Section 10.1 of the SRC on which the exemption from registration is claimed; and
- (2) The following statement must be made in bold face, prominent type: THE SECURITIES BEING OFFERED OR SOLD HEREIN HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE OF THE PHILIPPINES. ANY FUTURE OFFER OR SALE THEREOF IS SUBJECT TO REGISTRATION REQUIREMENTS UNDER THE CODE UNLESS SUCH OFFER OR SALE QUALIFIES AS AN EXEMPT TRANSACTION.

Qatar (ex-QFC)

For Residents of the State of Qatar

This Document has not been filed with, reviewed or approved by the Qatar Central Bank, the Qatar Financial Markets Authority, the Qatar Financial Centre Regulatory Authority or any other relevant Qatari governmental body or securities exchange or under any laws of the State of Qatar. This document does not constitute a public offering and is addressed only to the party to whom it has been delivered. No transaction will be concluded in Qatar and any inquiries or applications regarding the Product should be received, and allotments made, outside Qatar.



Qatar (ex-QFC) (Cont'd)

Regulatory Disclaimer

As per the QFCRA rulebooks (GENE 3.1.2) all marketing material need to (i) disclose the regulatory status of the distributing entity and (ii) specify if the document is directed to certain categories of clients. Therefore, the following disclaimer need to be incorporated:

State of Qatar

Deutsche Bank AG in the Qatar Financial Centre (registered no. 00032) is regulated by the Qatar Financial Centre Regulatory Authority (QFCRA). Deutsche Bank AG, Doha (QFC) Branch may only undertake the financial services activities that fall within the scope of its existing QFCRA license. Principal place of business in the QFC: Qatar Financial Centre, Tower, West Bay, Level 5, PO Box 14928, Doha, Qatar. Information distributed by Deutsche Bank AG, Doha (QFC) Branch relating to financial products or services regulated by the QFCRA are only available to Business Customers, as defined by the QFCRA.

Singapore

In Singapore, this document is issued by DWS Investments Singapore Limited. This document has not been reviewed by the Monetary Authority of Singapore.

This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of the fund(s) may not be circulated or distributed, nor may shares of the fund(s) be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor pursuant to Section 304 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") or (ii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

South Korea

This material deals with a specific product/investment strategy which is not registered in Korea. Therefore the material can not be used for Korean investors. Only passive communication to respond to a request from a Korean investor is allowed. This material can not be sent to a Korean investor unless the investor requests the material on an unsolicited basis or the investor is an existing client of the product. Also, it may be prudent to have some paper trail which can evidence the fact that the request was made by the investor on an unsolicited basis.

Spain

This document has not been prepared in accordance with the requirements of Spanish regulations for sales prospectus (Act 35/2003, as of 4th November, Collective Investment Schemes, RD 1082/2014, as of 13th July that approves Regulation of the previous Act, and Circular 3/2006, as of 26th October, sales prospectus). The prospectus of the Fund has not been registered at the Spanish regulator as there is no intention to distribute the shares in Spain through any public advertisement or any other similar way. This Fund will only be offered individualized to a limited number of qualified investors.

This document is confidential and will be of the exclusive use of the recipient specifically addressed.

Investors that acquire shares of this Fund in Spain will personally seek advice of any single matter related to their investment (including tax issues), from subscription, to holding and realization of the investment.



Sweden (where distributed by Deutsche Bank AG, Stockholm branch)

Deutsche Bank AG is authorised under German Banking Law (competent authority: European Central Bank and the BaFin, Germany's Federal Financial Supervisory Authority). Deutsche Bank AG Stockholm branch ("DBS", Bolagsverket nr. 516401-9985) is authorised by BaFin and regulated by Finansinspektionen for the conduct of licensed activities in Sweden, Denmark, Norway and Finland. Deutsche Bank branches operate within the EEA on the back of the legal entity (Deutsche Bank AG) EU Passports within the European Economic Area ("EEA"). Reference is made to European Union Regulatory Background and Corporate and Regulatory Disclosures at https://www.db.com/en/content/eu disclosures uk.htm. Details about the extent of our authorisation and regulation by BaFin and respective Nordic Region Financial Supervisory Authority are available from us on request.

Without limitation, this document and any attachment does not constitute an offer or a recommendation to enter into any transaction with DBS. This material and attachments is for information purposes only and is not intended to be an offer or an advice or recommendation or solicitation, or the basis for any contract to purchase or sell any security, or other instrument, or for DBS to enter into or arrange any type of transaction as a consequence of any information contained herein. The implicit or explicit views and recommendations expressed in marketing or other financial presentation material as well as any financial proposals are solely those of the issuer of such material, and forwarded to you on behalf of the contracting party. The views set out in this presentation are those of the author and may not necessarily the views of any other division within Deutsche Bank, including the Sales and Trading functions of the Corporate and Investment Bank or the Global Client Group of Deutsche Asset Management and Private Wealth Management: all services provided by these the Sales and Trading functions of the Corporate and Investment Bank are purely on a non-advised, execution-only basis. DB may engage in transactions in a manner inconsistent with the views discussed herein. DB trades or may trade as principal in the instruments (or related derivatives), and may have proprietary positions in the instruments (or related derivatives) discussed herein. DB may make a market in the instruments (or related derivatives) discussed herein. Sales and Trading personnel are compensated in part based on the volume of transactions effected by them. You may not distribute this document, in whole or in part, without our express written permission.

DBS is solely acting for and on behalf of Deutsche Bank AG and/or any of its affiliates. Potential investors should be aware that if they decide to enter into a transaction with Deutsche Bank AG or any of its affiliates acting in their capacity as principal to the transaction ("contracting party"), any and all agreements will be entered into with that contracting party (unless re-negotiated) and pursuant to the financial laws and regulations of the country where the contracting party is licensed. Unless DBS is entering into a separate and explicit contractual relationship with you for the provision of investment services, it is neither obliged to categorise you in accordance with MiFID nor perform MiFID suitability and/or appropriateness assessment (as enacted into Swedish laws and regulations). The investments or services mentioned in this material or an attachment thereto may not be appropriate for all investors and before entering into a transaction you should take steps to ensure that you fully understand the transaction and have made an independent assessment of the appropriateness of the transaction in the light of your own objectives and circumstances, including the possible risks and benefits of entering into such transaction. You should also consider seeking advice from your own advisers in making this assessment. If you decide to enter into a transaction with a contracting party you do so in reliance on your own judgment. For general information regarding the nature and risks and types of financial instruments please go to www.globalmarkets.db.com/riskdisclosures.

DB SPECIFICALLY DISCLAIMS ALL LIABILITY FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR OTHER LOSSES OR DAMAGES INCLUDING LOSS OF PROFITS INCURRED BY YOU OR ANY THIRD PARTY THAT MAY ARISE FROM ANY RELIANCE ON THIS DOCUMENT OR FOR THE RELIABILITY, ACCURACY, COMPLETENESS OR TIMELINESS THEREOF.

Switzerland

The distribution of the Interests in Switzerland will be exclusively made to, and directed at, qualified investors (the "Qualified Investors"), as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended ("CISA"), and its implementing ordinance. Accordingly, the Fund has not been and will not be registered with the Swiss Financial Market Supervisory Authority ("FINMA"). This Memorandum and/or any other offering materials relating to the Interests may be made available in Switzerland solely to Qualified Investors.

This document is strictly for the private use of qualified investors and is being presented for informational and discussion purposes only. Any reproduction and/or redistribution thereof, in whole or in part, and any disclosure of its content without our consent is strictly forbidden.



Switzerland (cont'd)

The Fund Documents as well as the annual report of the Fund can be obtained free of charge from the representative in Switzerland whose details are set out below. In respect of the Interests distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the Swiss representative.

Swiss representative and paying agent: DWS CH AG, Hardstrasse 201, CH-8021 Zurich, Switzerland.

Payment of retrocessions/distribution fees and rebates

The Manager and its affiliates may pay retrocessions/distribution fees in order to remunerate the distribution activities in respect of the Fund and/or the Interests in or from Switzerland. Retrocessions/distribution fees will be not construed as rebates even if they are ultimately transferred in whole or in part to an Investor. The recipients of the retrocessions/distribution fees must ensure transparent disclosure and inform Investors, unsolicited and free of charge, about the amount of the compensation they may receive for distribution. On request, the recipients of the retrocessions/distribution fees must disclose the amounts they actually receive for the distribution of the Fund and/or the Interests held by the Investors concerned.

As part of the distribution of the Fund and/or the Interests in or from Switzerland, the Manager and its affiliates may pay, upon request, rebates directly to Investors. The purpose of the rebates is to reduce the fees or costs payable by an Investor. Rebates are permitted provided that (i) they are paid from the fees due to the Manager and its affiliates, so that they are not charged additionally to the Fund and/or the Investors; (ii) they are granted on the basis of objective criteria, (iii) they are granted within the same timeframe and to the same extent to all Investors who qualify on the basis of these objective criteria and demand rebates. The objective criteria to grant rebates are:

the investment volume of an Investor in the Fund or in the product range of the Manager;

the amount of the fees generated by the Investor;

the expected investment period of the Investor;

the willingness of the Investor to provide support in the launch phase of the Fund.

At the request of the Investor, the Manager must disclose free of charge the corresponding amounts of the rebates.

Taiwan

The interests described in this document may be made available for investment outside Taiwan by investors residing in Taiwan, but may not be offered or sold in Taiwan. The interests described in this document are not registered or approved by FSC of Taiwan ROC and could not be offered, distributed or resold to the public in Taiwan. The investment risk borne by unregistered and unapproved interests could cause investors loss part of or all investment amount. The securities may be made available for purchase outside Taiwan by investors residing in Taiwan, but may not be offered or sold in Taiwan.

Thailand

This material was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. It is intended for information purposes only. It does not constitute investment advice, a recommendation, an offer, solicitation, the basis for any contract to purchase or sell any security or other instrument, or for Deutsche Bank AG or its affiliates to enter into or arrange any type of transaction as a consequence of any information contained herein. Neither Deutsche Bank AG nor any of its affiliates gives any warranty as to the accuracy, reliability or completeness of information which is contained in this document.

None for: Denmark, Finland, Malta, Norway



Switzerland (cont'd)

The Fund Documents as well as the annual report of the Fund can be obtained free of charge from the representative in Switzerland whose details are set out below. In respect of the Interests distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the Swiss representative.

Swiss representative and paying agent: DWS CH AG, Hardstrasse 201, CH-8021 Zurich, Switzerland.

Payment of retrocessions/distribution fees and rebates

The Manager and its affiliates may pay retrocessions/distribution fees in order to remunerate the distribution activities in respect of the Fund and/or the Interests in or from Switzerland. Retrocessions/distribution fees will be not construed as rebates even if they are ultimately transferred in whole or in part to an Investor. The recipients of the retrocessions/distribution fees must ensure transparent disclosure and inform Investors, unsolicited and free of charge, about the amount of the compensation they may receive for distribution. On request, the recipients of the retrocessions/distribution fees must disclose the amounts they actually receive for the distribution of the Fund and/or the Interests held by the Investors concerned.

As part of the distribution of the Fund and/or the Interests in or from Switzerland, the Manager and its affiliates may pay, upon request, rebates directly to Investors. The purpose of the rebates is to reduce the fees or costs payable by an Investor. Rebates are permitted provided that (i) they are paid from the fees due to the Manager and its affiliates, so that they are not charged additionally to the Fund and/or the Investors; (ii) they are granted on the basis of objective criteria, (iii) they are granted within the same timeframe and to the same extent to all Investors who qualify on the basis of these objective criteria and demand rebates. The objective criteria to grant rebates are:

the investment volume of an Investor in the Fund or in the product range of the Manager;

the amount of the fees generated by the Investor;

the expected investment period of the Investor;

the willingness of the Investor to provide support in the launch phase of the Fund.

At the request of the Investor, the Manager must disclose free of charge the corresponding amounts of the rebates.

Taiwan

The interests described in this document may be made available for investment outside Taiwan by investors residing in Taiwan, but may not be offered or sold in Taiwan. The interests described in this document are not registered or approved by FSC of Taiwan ROC and could not be offered, distributed or resold to the public in Taiwan. The investment risk borne by unregistered and unapproved interests could cause investors loss part of or all investment amount. The securities may be made available for purchase outside Taiwan by investors residing in Taiwan, but may not be offered or sold in Taiwan.

Thailand

This material was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. It is intended for information purposes only. It does not constitute investment advice, a recommendation, an offer, solicitation, the basis for any contract to purchase or sell any security or other instrument, or for Deutsche Bank AG or its affiliates to enter into or arrange any type of transaction as a consequence of any information contained herein. Neither Deutsche Bank AG nor any of its affiliates gives any warranty as to the accuracy, reliability or completeness of information which is contained in this document.

None for: Denmark, Finland, Malta, Norway



For Investors in the United States

The securities described herein will not be registered under the Securities Act of 1933 ("Securities Act"), as amended, and the issuer of such securities will not be registered under the Investment Company Act of 1940 (the "1940 Act"), as amended. Such securities may only be offered to a person or entity who (a) either is a "Qualified Institutional Buyer" under Rule 144A, or is an "accredited investor" as defined in Rule 501(a) of Regulation D under the Securities Act of 1933 or is not a "US Person" in accordance with Regulation S, each as defined under the Securities Act, as amended, and the rules promulgated there under and (b) in the case of US persons, is a "qualified purchaser" as defined under the Investment Company Act as amended (the "1940 Act"), and the rules promulgated there under. The securities offered herein will not be recommended by any United States Federal or State Securities Commission or regulatory authority. Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this document. Any representation to the contrary is a criminal offense. The securities may not be offered, sold, transferred, or re-sold except pursuant to a valid exemption under the Securities Act. An investor shall not purchase the securities with a view to the resale, distribution, or other disposition thereof in violation of the Securities Act.

For Investors in Canada

No securities commission or similar authority in Canada has reviewed or in any way passed upon this document or the merits of the securities described herein and any representation to the contrary is an offence. There are risks associated with an investment in the fund. The materials provided here in are submitted on a confidential basis for use by a limited number of qualified purchasers solely in connection with the consideration of the purchase of these securities on a "private placement" basis and only in those jurisdictions to whom they may be lawfully offered for sale, and there in only by persons permitted to sell such securities. The securities described herein may only be transferred in accordance with resale restrictions under applicable securities laws and investors are advised to seek legal advice for the resale restrictions applicable to them.

Information contained herein is qualified in its entirety by the Memorandum and investors are advised to refer to such Memorandum. These materials are not, and under no circumstances to be construed as, an advertisement or a public offering of the securities described herein. These materials may not be reproduced in whole or in part and its use for any purpose other than to evaluate an investment in the securities described herein is prohibited.

Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. Par la réception de ce document, chaque investisseur canadien confirme par les présentes qu'il a expressément exigé que tous les documents faisant foi ou se rapportant de quelque manière que ce soit à la vente des valeurs mobilières décrites aux présentes (incluant, pour plus de certitude, toute confirmation d'achat ou tout avis) soient rédigés en anglais seulement.